GSK’s Avandaryl Approved, But Manufacturing Changes Are Still Pending
Executive Summary
GlaxoSmithKline's diabetes line extension product Avandaryl has cleared FDA, but the firm plans to move manufacturing for commercial supply of the drug out of its problematic Puerto Rico plant